How the 9/11 terrorist attacks encouraged the evolution of The One Health Initiative and what that means for the future of medicine.
You see a 48-year-old white man for his annual examination. . The patient is overweight with a body mass index (BMI) of 32. A screening chemistry panel is normal except for an aspartate aminotransferase (AST, formerly SGOT) level of 85 U/L (normal 15-50 U/L) and an alanine aminotransferase (ALT, formerly SGPT) level of 98 U/L (normal 5-50 U/L). He says you are the first doctor he has seen in more than 10 years and does not recall the last time he had a blood test.
The challenge of eliminating disparities in clinical trials is being addressed by the Eliminating Disparities in Clinical Trials (EDICT) project, which recognizes that broadening diversity in clinical trials will result in improved effectiveness and safety of future medicines, improved trial quality, and reduced discrepancies in health equity.
The benefits of implantable cardioverter-defibrillators (ICDs) have been shown in randomized clinical trials. The factors that affect the risk–benefit ratio in a community setting, however, have not been evaluated.
It is difficult to make generalizations about treatment of elderly diabetic patients with coronary artery disease (CAD).
We assessed how well dobutamine stress echocardiography predicted morbidity and mortality in 2349 patients with diabetes mellitus over a follow-up period of 13.2 years. Results showed that age, failure to achieve the target heart rate, and the percentage of ischemic segments were independent predictors of both mortality and cardiovascular morbidity. Using clinical and stress echocardiographic parameters, a simple model for risk stratification was developed.
According to a report in the August 2009 issue of Diabetes Care, even when patients with type 1 diabetes have excellent hemoglobin A1C levels, continuous glucose monitoring will be beneficial.
Large organizations with mobile workers, such as hospitals, face diminished productivity when communication is inefficient and its employees are unable to locate their coworkers in a timely manner.
RBX2660 from Rebiotix will be assessed in a randomized study involving 300 patients.
Our increasing ability to intervene in high-risk patients—with lower risks and greater chances for successful outcomes—is felt across the broad spectrum of cardiovascular disease. This is particularly evident in patients with dilated cardiomyopathy (DCM).
In response to the growing prevalence of gestational diabetes mellitus and its associated morbidities, much attention has been paid to the use of appropriate screening methodologies for the metabolic disorder.
Angiotensin-converting enzyme (ACE) inhibitors have been shown to be beneficial in the management of multiple cardiovascular disease states.
We assessed whether duration of nonischemic cardiomyopathy was related to the degree of benefit from implantable cardioverter-defibrillator (ICD) insertion. Subjects who had a recent diagnosis of nonischemic cardiomyopathy had at least a similar benefit from ICD insertion as did those with a remote diagnosis. These results indicate that ICD therapy should be considered in such patients as soon as they are diagnosed and once reversible causes of left ventricular dysfunction have been excluded.
We recruited 973 patients (mean age, 81 years) with atrial fibrillation from the primary care setting and randomly assigned them to receive anticoagulation with warfarin or aspirin.
Conflicts between identity and depressive symptoms may account for the significant delays in help-seeking by patients with depression, according to research published October 2, 2012 in BMC Psychiatry.
The risk calculator reported in the Lee et al paper was developed to predict the 10-year cardiovascular (CV) disease probability in an American Indian population.
Adding opioids or skeletal muscle relaxants to traditional nonsteroidal anti-inflammatory drug (NSAID) treatment for acute lower back pain (LBP) provides little improvement in pain management,